- €50.59bn
- €45.99bn
- $4.15bn
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Forte Biosciences jumps on $2.2 bln Argenx takeover bid
Deals of the day-Mergers and acquisitions
Press Digest: Wall Street Journal - July 27
Argenx to buy Forte Biosciences for about $2.2 billion
Brief: Argenx To Buy Forte Biosciences For $2.20 Bln
Argenx rises after Q2 results beat driven by Vyvgart sales
Corrected: UPDATE 2-Argenx's Vyvgart sales jump in second quarter, shares climb
Netherlands' Argenx Q2 net sales rise
Argenx's Vyvgart sales rose in the second quarter
Brief: Argenx Q2 Net Income USD 472 Million
Argenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles
Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP
Netherlands' Argenx Q4 sales rise 90%, posts first profitable year